Understanding the Controlled Substances Act and Drug Scheduling
By: Tom Pool, CSAPA
Executive Administrator, Drug Free Business and retired DEA S/A
Employers may be concerned by news of the proposal to reschedule marijuana from Schedule I to Schedule III. The Controlled Substances Act (CSA) classifies drugs and other substances into five schedules based on their accepted medical use, potential for abuse, and risk of dependence. This classification helps regulate these substances’ manufacture, distribution, and use.
How Drugs Are Scheduled
Drugs can be added, removed, or moved between schedules through a process initiated by the Drug Enforcement Administration (DEA), the Department of Health and Human Services (HHS), or by petitions from manufacturers, medical associations, public interest groups, or individuals.
When a request is made, the DEA investigates the drug’s abuse potential, medical use, and safety. The DEA then seeks a scientific and medical evaluation from HHS, whose findings are binding. The DEA Administrator uses this information to determine whether the drug should be scheduled or removed from control.
Criteria for Drug Scheduling
A drug is only controlled if it has a potential for abuse. While the CSA doesn’t define “potential for abuse,” factors considered include:
- Reports of misuse causing health or safety hazards
- Significant diversion from legal drug supply chains
- Self-administration without medical guidance
- Chemical similarity to other controlled substances with known abuse potential
When classifying a drug, the following factors are also examined:
- Scientific evidence of effects and risks
- History and patterns of abuse
- Public health risks
- Addiction potential
- Whether it’s a precursor to an already controlled substance
The Five Drug Schedules
The CSA categorizes substances into five schedules:
Schedule I (High abuse potential, no accepted medical use)
- Examples: Heroin, LSD, marijuana, GHB
- Since Schedules II, III, IV, and V drugs all have some accepted medical use, any abused drug without a current approved medical use must be placed in Schedule I, even if its abuse potential is lower than that of drugs in Schedules II through V.
Schedule II (High abuse potential, accepted medical use with restrictions)
- Examples: Morphine, cocaine, methamphetamine, fentanyl
Schedule III (Moderate abuse potential, accepted medical use)
- Examples: Anabolic steroids, some codeine products, barbiturates
Schedule IV (Low abuse potential, accepted medical use)
- Examples: Alprazolam (Xanax), diazepam (Valium), clonazepam
Schedule V (Lowest abuse potential, accepted medical use)
- Examples: Cough medicines with codeine
The Scheduling Process
Once the DEA decides to control, reschedule, or decontrol a drug, it publishes a proposal in the Federal Register, inviting public comments. If no hearing is requested, the DEA finalizes the decision. If a hearing is requested, an Administrative Law Judge reviews the evidence before the DEA makes a final ruling.
Interested parties can appeal the decision in a U.S. Court of Appeals within 30 days. However, the new classification remains in effect unless overturned by the court.
Emergency Scheduling and Controlled Substance Analogs
To address urgent public safety threats, the DEA can temporarily place a substance in Schedule I for up to two years, with a possible one-year extension while formal scheduling procedures are underway.
Controlled Substance Analogs, which are chemically similar to Schedule I or II drugs but not formally scheduled, can also be regulated as Schedule I substances if intended for human consumption.
International Drug Scheduling
U.S. drug scheduling decisions may be influenced by international treaty obligations, such as the Single Convention on Narcotic Drugs (1961) and the Convention on Psychotropic Substances (1971). These agreements require the U.S. to control certain substances at specific levels to comply with global drug policies.
Conclusion
The Controlled Substances Act provides a structured process for regulating drugs based on medical value and abuse potential. Understanding this framework helps policymakers, medical professionals, and the public navigate drug classification and control measures effectively.
